share_log

Needham Maintains Buy on KalVista Pharma, Maintains $35 Price Target

Moomoo 24/7 ·  Mar 11 15:52

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment